Biogen (BIIB) Approves $5B Buyback
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Biogen (BIIB) PT Lowered to $300 at H.C. Wainwright
March 25, 2019 7:49 AM EDTH.C. Wainwright analyst Andrew Fein lowered the price target on Biogen (NASDAQ: BIIB) to $300.00 (from $363.00) while maintaining a Buy rating following the discontinuation of Aducanumab. Despite limited details around the data, Fein thinks this development nevertheless points to the insufficiency in the current... More
